Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
AEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.
OpenZedge, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpencbdMD, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenXtant Medical Holdings, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenAgEagle Aerial Systems, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenMAIA Biotechnology, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenLineage Cell Therapeutics, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenIdaho Strategic Resources, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenImpact BioMedical, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenNew Concept Energy, Inc has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenBlockchAIn has a real 40 MW operating data center and an AI/HPC infrastructure pitch, but the latest filings show margin pressure, thin cash, heavy customer and energy-provider concentration, related-party control and non-binding pipeline claims.
OpenAditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
OpenADIL has a genetically targeted alcohol-use-disorder drug candidate, a proposed European partner, and a possible simpler Phase 3 path, but the company has no product revenue and cash only into the second half of 2026.
OpenAcurx is a no-revenue antibiotic developer with a Phase 3-ready CDI lead asset, a new recurrent-CDI pilot plan, repeated equity financing, and explicit going-concern pressure. The question is whether ibezapolstat gets financed into proof before dilution become
OpenActuate has a company-defining elraglusib Phase 2 pancreatic-cancer survival signal and a new oral IND, but the same source set shows no product revenue, going-concern disclosure, and a need for capital beyond July 2026.
OpenAcrivon has an AP3-guided oncology platform, a lead ACR-368 endometrial-cancer catalyst, and cash runway into Q3 2027, but it is still pre-revenue and dependent on clinical data, diagnostics, and future financing.
OpenAclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.
OpenABVC looks like a tiny biotech, a licensing company, a CDMO, and a Taiwan real-asset story in the same filing. The first proof gate is whether cash, controls, and partners can catch up to the size of the pipeline.
OpenAchieve has late-stage cytisinicline data, an accepted smoking-cessation NDA, and a fresh financing. The catch is that management now expects a manufacturing-driven FDA Complete Response Letter before any U.S. launch.
OpenAdicet is trying to turn prula-cel from a promising autoimmune CAR-T idea into a pivotal-trial story before its disclosed runway reaches the second half of 2027.
Open